---
title: Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatin in
  patients with HER2-negative BC and HRD -long-term survival of the GeparOLA study
date: '2025-02-25'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39998850/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250225171113&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: For HER2-negative eBC with HRD, olaparib showed a tendency
  for inferior outcomes compared to carboplatin, particularly in patients without
  g/tBRCA1/2mut. In patients with g/tBRCA1/2mut olaparib may replace ...'
disable_comments: true
---
CONCLUSION: For HER2-negative eBC with HRD, olaparib showed a tendency for inferior outcomes compared to carboplatin, particularly in patients without g/tBRCA1/2mut. In patients with g/tBRCA1/2mut olaparib may replace ...